Compare OC & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OC | CORT |
|---|---|---|
| Founded | 1938 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 9.7B |
| IPO Year | 2006 | 2001 |
| Metric | OC | CORT |
|---|---|---|
| Price | $114.33 | $90.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 5 |
| Target Price | ★ $148.50 | $141.00 |
| AVG Volume (30 Days) | ★ 951.5K | 649.2K |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.50 | 0.09 |
| Revenue | N/A | ★ $761,407,000.00 |
| Revenue This Year | N/A | $50.53 |
| Revenue Next Year | $2.72 | $48.90 |
| P/E Ratio | ★ $77.92 | $1,194.51 |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $97.53 | $28.66 |
| 52 Week High | $159.91 | $126.38 |
| Indicator | OC | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 43.13 | 26.74 |
| Support Level | $106.24 | $87.44 |
| Resistance Level | $129.58 | $95.11 |
| Average True Range (ATR) | 3.87 | 6.07 |
| MACD | 0.86 | -2.26 |
| Stochastic Oscillator | 49.10 | 15.94 |
Owens-Corning Inc is a building products company that offers roofing products and systems, insulation products (hermal and acoustical batts, loose fill insulation, spray foam insulation, wet use chopped strand, etc.), and doors and door systems. The company's reportable segments are: Roofing, Insulation, and Doors. Maximum revenue is generated from the Roofing segment, which manufactures and sells residential roofing shingles, oxidized asphalt materials, roofing components, and composite lumber mainly used in residential construction. This segment also manufactures and sells glass mat and specialty veil materials used in building and construction applications. Geographically, the company generates maximum revenue from the United States, followed by Europe, Asia-Pacific, and other markets.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.